Fuji Pharma Co., Ltd. (4554.T)
JPY 1361.0
(0.29%)
JPY 1361.0
(0.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.85 Billion JPY | 2.14% |
| 2022 | 3.77 Billion JPY | 12.78% |
| 2021 | 3.34 Billion JPY | 6.69% |
| 2020 | 3.13 Billion JPY | -24.78% |
| 2019 | 4.17 Billion JPY | -4.96% |
| 2018 | 4.39 Billion JPY | 1.78% |
| 2017 | 4.31 Billion JPY | 20.91% |
| 2016 | 3.56 Billion JPY | 9.75% |
| 2015 | 3.25 Billion JPY | 2.46% |
| 2014 | 3.17 Billion JPY | -2.7% |
| 2013 | 3.26 Billion JPY | -6.7% |
| 2012 | 3.49 Billion JPY | -19.46% |
| 2011 | 4.33 Billion JPY | 10.22% |
| 2010 | 3.93 Billion JPY | 26.15% |
| 2009 | 3.12 Billion JPY | 16.06% |
| 2008 | 2.68 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.58 Billion JPY | 1231.43% |
| 2024 Q1 | -140 Million JPY | -109.62% |
| 2024 Q3 | 772 Million JPY | -51.26% |
| 2023 Q3 | 579 Million JPY | -8.68% |
| 2023 Q4 | 1.45 Billion JPY | 151.3% |
| 2023 FY | 3.85 Billion JPY | 2.14% |
| 2023 Q1 | 908 Million JPY | 100.88% |
| 2023 Q2 | 634 Million JPY | -30.18% |
| 2022 Q2 | 1.15 Billion JPY | -26.38% |
| 2022 Q1 | 1.56 Billion JPY | 722.31% |
| 2022 FY | 3.77 Billion JPY | 12.78% |
| 2022 Q4 | 452 Million JPY | -49.78% |
| 2022 Q3 | 900 Million JPY | -21.74% |
| 2021 Q2 | 988 Million JPY | -41.81% |
| 2021 FY | 3.34 Billion JPY | 6.69% |
| 2021 Q1 | 1.69 Billion JPY | 85.37% |
| 2021 Q3 | 914 Million JPY | -7.49% |
| 2021 Q4 | -251 Million JPY | -127.46% |
| 2020 Q1 | 1.05 Billion JPY | 135.57% |
| 2020 FY | 3.13 Billion JPY | -24.78% |
| 2020 Q2 | 682 Million JPY | -35.23% |
| 2020 Q3 | 488 Million JPY | -28.45% |
| 2020 Q4 | 916 Million JPY | 87.7% |
| 2019 Q4 | 447 Million JPY | -64.5% |
| 2019 FY | 4.17 Billion JPY | -4.96% |
| 2019 Q1 | 1.6 Billion JPY | 90.17% |
| 2019 Q2 | 862 Million JPY | -46.29% |
| 2019 Q3 | 1.25 Billion JPY | 46.06% |
| 2018 Q2 | 550 Million JPY | -68.12% |
| 2018 Q1 | 1.72 Billion JPY | 129.08% |
| 2018 Q3 | 1.27 Billion JPY | 131.27% |
| 2018 Q4 | 844 Million JPY | -33.65% |
| 2018 FY | 4.39 Billion JPY | 1.78% |
| 2017 FY | 4.31 Billion JPY | 20.91% |
| 2017 Q3 | 1.28 Billion JPY | 28.7% |
| 2017 Q2 | 1 Billion JPY | -21.51% |
| 2017 Q1 | 1.27 Billion JPY | 78.18% |
| 2017 Q4 | 753 Million JPY | -41.49% |
| 2016 Q4 | 715 Million JPY | -30.85% |
| 2016 FY | 3.56 Billion JPY | 9.75% |
| 2016 Q1 | 834 Million JPY | -19.65% |
| 2016 Q2 | 985 Million JPY | 18.11% |
| 2016 Q3 | 1.03 Billion JPY | 4.97% |
| 2015 Q3 | 773 Million JPY | 24.48% |
| 2015 FY | 3.25 Billion JPY | 2.46% |
| 2015 Q1 | 819 Million JPY | -14.6% |
| 2015 Q2 | 621 Million JPY | -24.18% |
| 2015 Q4 | 1.03 Billion JPY | 34.28% |
| 2014 FY | 3.17 Billion JPY | -2.7% |
| 2014 Q4 | 959 Million JPY | 46.86% |
| 2014 Q3 | 653 Million JPY | -10.79% |
| 2014 Q2 | 732 Million JPY | -11.7% |
| 2014 Q1 | 829 Million JPY | -20.9% |
| 2013 Q4 | 1.04 Billion JPY | 73.51% |
| 2013 Q3 | 604 Million JPY | -19.47% |
| 2013 FY | 3.26 Billion JPY | -6.7% |
| 2013 Q2 | 750 Million JPY | -12.69% |
| 2013 Q1 | 859 Million JPY | -51.84% |
| 2012 Q1 | 461.85 Million JPY | -73.61% |
| 2012 Q4 | 1.78 Billion JPY | 142.05% |
| 2012 Q3 | 736.85 Million JPY | 43.71% |
| 2012 FY | 3.49 Billion JPY | -19.46% |
| 2012 Q2 | 512.72 Million JPY | 11.02% |
| 2011 Q4 | 1.75 Billion JPY | 93.52% |
| 2011 Q1 | 953.15 Million JPY | -34.44% |
| 2011 FY | 4.33 Billion JPY | 10.22% |
| 2011 Q3 | 904.48 Million JPY | 23.68% |
| 2011 Q2 | 731.32 Million JPY | -23.27% |
| 2010 Q4 | 1.45 Billion JPY | 66.58% |
| 2010 Q2 | 667.27 Million JPY | -29.24% |
| 2010 Q3 | 872.74 Million JPY | 30.79% |
| 2010 Q1 | 943.06 Million JPY | -40.02% |
| 2010 FY | 3.93 Billion JPY | 26.15% |
| 2009 Q1 | 545.03 Million JPY | 0.0% |
| 2009 Q2 | 398.43 Million JPY | -26.9% |
| 2009 Q3 | 605.22 Million JPY | 51.9% |
| 2009 Q4 | 1.57 Billion JPY | 159.78% |
| 2009 FY | 3.12 Billion JPY | 16.06% |
| 2008 FY | 2.68 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | 24.545% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 98.198% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 101.089% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 97.75% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | 2073.291% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 87.708% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 59.445% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 92.776% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | -438.827% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 70.699% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | 33.517% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | -96.436% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | 880.972% |
| Tsumura & Co. | 20.01 Billion JPY | 80.727% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | 3.958% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | 23.392% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 78.139% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 60.295% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | 35.839% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 225.3% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | 0.924% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | 575.317% |
| MedRx Co., Ltd | -933 Million JPY | 513.505% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | 25.116% |
| Solasia Pharma K.K. | -1.13 Billion JPY | 438.718% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 262.785% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 40.646% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 79.572% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | 653.168% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 80.042% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | 11.964% |